A phase I trial (NCT02381314) evaluates the safety of enoblituzumab in combination with ipilimumab in patients with NSCLC and other B7-H3 expressing solid malignancies (NCT02381314). The gene discussed is CD276; the disease is non-small cell lung carcinoma.